

AD _____

GRANT NUMBER DAMD17-94-J-4190

TITLE: Breast Tumorigenesis: Interaction of Two Signaling
Pathways--TGF--beta versus Estrogen Receptor

PRINCIPAL INVESTIGATOR: Xiao-Fan Wang, Ph.D.
Jonathan Yingling

CONTRACTING ORGANIZATION: Duke University
Durham, North Carolina 27710

REPORT DATE: October 1996

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19970117 094

DTIC QUALITY INSPECTED 1

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1996	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 95 - 31 Aug 96)	
4. TITLE AND SUBTITLE Breast Tumorigenesis: Interaction of Two Signaling Pathways--TGF--beta versus Estrogen Receptor			5. FUNDING NUMBERS DAMD17-94-J-4190	
6. AUTHOR(S) Xiao-Fan Wang, Ph.D. Jonathan Yingling				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Duke University Durham, North Carolina 27710			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, MD 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) The Smad protein family has been genetically implicated in transforming growth factor β (TGF- β)-like signaling pathways in <i>Drosophila</i> and <i>Caenorhabditis elegans</i> . To investigate the role of these proteins in mammalian signaling pathways, we have isolated and studied two murine Smads, Smad1 and Smad5. Using antibodies against Smad1 and Smad5, we show that these two Smads and an immunogenically related protein, presumably also a Smad, are phosphorylated in a time- and dose-dependent manner in response to TGF- β . Bone morphogenetic protein 2, a TGF- β superfamily ligand, induces phosphorylation of only the related Smad protein. Thus, TGF- β superfamily members may use overlapping yet distinct Smads to mediate their intracellular signals. Furthermore, transient overexpression of either Smad1 or Smad5 causes growth arrest, implicating the Smads in growth regulation. This work provides strong biochemical and preliminary functional evidence that Smad1 and Smad5 represent prototypic members of a family of mammalian proteins that may serve as mediators of signaling pathways for TGF- β superfamily members.				
14. SUBJECT TERMS Breast Cancer, Signal Transduction, Estrogen Receptor, Tumorigenesis, Transforming Growth Factor Beta, Growth Factors, Humans, Anatomical Samples, TGF-Beta			15. NUMBER OF PAGES 14	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

X Where copyrighted material is quoted, permission has been obtained to use such material.

X Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

X Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

 For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

X In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

X In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

X In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Jonathan Yingling 9-30-96
PI - Signature Date

9/30/96

Table of Contents

Cover Page	1
Report Documentation Page	2
Foreword	3
Table of Contents	4
Introduction	5
Progress Report (Body)	6, 7
Conclusions	8
References	9
Appendix	

A. INTRODUCTION

Breast cancer is the most common cancer in women in the United States. Although endocrine therapy has proven useful in treating approximately one-third of these patients, the tumors inevitably progress to a hormone independent state and no longer respond to these therapies. Thus, it is the goal of this research project to characterize the molecular basis of the TGF- β growth inhibitory in hopes of elucidating additional therapeutic targets.

TGF- β s are a group of multifunctional peptide hormones that play critical roles in many normal cellular processes including the regulation of proliferation, differentiation, extracellular matrix deposition, cell adhesion and migration (11). Perhaps TGF- β s most critical biological activity is its ability to inhibit the growth of a wide variety of cell types including breast epithelia (8). Therefore, loss of components of the TGF- β growth inhibitory pathway in breast epithelia would be expected to contribute to the genesis and progression of breast cancer. Loss of TGF- β responsiveness in MCF-7 cells has been correlated with loss of the type II TGF- β receptor and increased tumorigenesis. Reintroduction of the TGF- β type II receptor in these MCF-7 cells reverses this tumorigenic phenotype indicating the importance of this pathway in preventing breast tumorigenesis (9).

Significant progress has been made over the last 5 years to elucidate the molecular events at the cell membrane involving receptor activation which initiate TGF- β s intracellular signaling pathway. In addition, nuclear events involving induction of cyclin-dependent kinase inhibitors (p15 and p21) have been implicated in mediating TGF- β s growth inhibitory signal (4), (1). However, the nature of the cytoplasmic signaling cascade which transduces the signal from the membrane to the nucleus is just beginning to be resolved. Genetic analyses in *Drosophila* and *C. elegans* have led to the isolation of a variety of components of the TGF- β -like pathway including ligands and receptors which are homologous to those identified in vertebrates. The most recent addition to the list of genetically implicated proteins in *Drosophila* and *C. elegans* is the MAD (*Drosophila*) or SMA (*C. elegans*) family of proteins (7), (6). Mutation in these genes causes phenotypes analogous to those of the TGF- β -like receptors in these organisms thus implicating them in a downstream signaling pathway. Additional evidence from vertebrates is the discovery of a tumor suppressor gene on chromosome 18q which is deleted in ~50% of human pancreatic tumors (2). This gene, called DPC4, is a member of the MAD and SMA family by virtue of it containing the invariant MH1 and MH2 domains at its amino- and carboxy-termini, respectively.

The molecular basis of the role of the MAD family in the TGF- β pathway remains poorly understood. To address this issue we have cloned three murine members of this family termed Smad1, Smad2 and Smad5. We have examined the functional role of two of these proteins, Smad 1 and Smad5, in mediation of the TGF- β pathway in a normal murine mammary epithelial cell line, NMuMg. The results from these studies are summarized in the next section and a manuscript reprint is included in the Appendix.

B. PROGRESS REPORT

In the past twelve months my work has focused on the cloning and characterization of vertebrate members of the MAD family of proteins which have been genetically implicated in TGF- β -like pathways in *Drosophila* and *C. elegans*. Three full length proteins have been cloned from a murine cDNA library, mSmad1, mSmad2 and mSmad5 and antibodies have been generated against mSmad1 and mSmad5. We have utilized these antibodies in a series of experiments in NMuMg and L6 (rat myoblasts) cells to study the involvement of these proteins in TGF- β s growth inhibitory pathway.

Although the level of these proteins is not changed within 24 hours of TGF- β treatment (data not shown), two endogenous Smads are rapidly, but transiently phosphorylated in response to TGF- β (Appendix Fig. 2A). Both antibodies recognize the same two proteins by immunoprecipitation, a 52 kDa and 56 kDa protein. The induced phosphorylation is primarily on serine residues (~90%) with minimal threonine phosphorylation (~10%) as determined by phosphoamino acid analysis (data not shown). This inducible phosphorylation is not specific to NMuMg cells since the same effect is seen in L6 (Appendix Fig. 2C) cells and Mv1Lu cells (data not shown). The dose dependence of this inducible phosphorylation was determined to ensure that the phosphorylation was induced at physiological concentrations of TGF- β (Appendix Fig. 3). TGF- β at 10 pM induced a 3-fold increase in phosphorylation.

TGF- β -like ligands from *Drosophila* and *C. elegans* are most closely related to mammalian bone morphogenetic proteins (BMPs) (3). BMPs have been shown to elicit multiple effects on many different cell types including inhibition of cellular proliferation (3). BMP-2 has been shown to initiate its signaling cascade by binding a heteromeric complex of transmembrane serine/threonine kinase receptors at the cell surface (5). This mechanism is analogous to the TGF- β receptor system (10). However, the similarity between the cytoplasmic pathways that lead to the biological effects of TGF- β and BMP-2 is unknown. The NMuMg cell line is potently inhibited by BMP-2 causing a G1 growth arrest (unpublished results) which afforded us the opportunity to determine if endogenous Smad phosphorylation is induced by BMP-2. Unlike TGF- β , BMP-2 only causes inducible phosphorylation of one endogenous Smad protein (Appendix Fig. 4). However, this protein appears to be identical to one of the proteins which is phosphorylated in response to TGF- β . The possibility that one Smad lies downstream in both the TGF- β and BMP-2 pathways is currently under investigation. The issue of overlapping or distinct Smad proteins downstream of TGF- β superfamily members is currently a source of considerable debate in the field. Our characterization of Smad proteins in NMuMg cells which respond to both TGF- β and BMP-2 should resolve this issue.

To address the functional role of the Smad proteins in TGF- β signaling we cloned mSmad1 and mSmad5 into mammalian expression vectors. Attempts to establish stable cell lines constitutively overexpressing either Smad1 in L6 cells or Smad5 in NMuMg cells were unsuccessful. This result was not unexpected since DPC4 is a tumor suppressor gene and thus suspected to have growth suppressive effects. Consequently we used a modified transient growth arrest assay to assess the ability of Smad1 or Smad5 to

cause a growth arrest in L6 cells. Overexpression of Smad1 or Smad5 causes 30-40% growth inhibition compared to 10% for control transfectants (Appendix Fig. 5). Therefore, Smad1 and Smad5 like DPC4 exhibit growth inhibitory properties, a phenotypic hallmark of TGF- β .

C. CONCLUSIONS

Significant progress has been made in elucidation of a potential downstream signaling pathway involving the Smad family of proteins in TGF- β superfamily signaling pathways. Specifically, two endogenous Smads are phosphorylated in response to TGF- β while only one of these is phosphorylated in response to BMP-2. Furthermore, these proteins when overexpressed in mammalian cells leads to a growth arrest, a phenotypic hallmark of TGF- β . Together with the genetic evidence from *Drosophila* and *C. elegans*, our results establish the Smads as effectors of growth inhibitory signals initiated by TGF- β and BMP-2 in mammalian cells. Our results further suggest that overlapping, yet distinct Smads may be involved in TGF- β superfamily signaling cascades. Future studies will reveal which Smads play a significant role in the pathological process of breast carcinogenesis, analogous to the role of DPC4 in pancreatic carcinogenesis.

D. APPENDIX

Yingling, J.M., Das, P., Savage, C., Zhang, M., Padgett, R.W., and X.F. Wang. 1996. Mammalian dwarfins are phosphorylated in response to transforming growth factor β and are implicated in control of cell growth. *Proc Natl Acad Sci USA* **93**:8940-4.

E. REFERENCES

1. Datto, M. B., Y. Li, J. F. Panus, D. J. Howe, Y. Xiong, and X. F. Wang. 1995. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. *Proc Natl Acad Sci U S A* **92**:5545-9.
2. Hahn, S. A., M. Schutte, A. T. Hoque, C. A. Moskaluk, L. T. da Costa, E. Rozenblum, C. L. Weinstein, A. Fischer, C. J. Yeo, R. H. Hruban, and S. E. Kern. 1996. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science* **271**:350-3.
3. Kingsley, D. M. 1994. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. *Genes Dev* **8**:133-46.
4. Li, J. M., M. A. Nichols, S. Chandrasekharan, Y. Xiong, and X. F. Wang. 1995. Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. *J Biol Chem* **270**:26750-3.
5. Liu, F., F. Ventura, J. Doody, and J. Massague. 1995. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. *Mol Cell Biol* **15**:3479-86.
6. Savage, C., P. Das, A. L. Finelli, S. R. Townsend, C. Y. Sun, S. E. Baird, and R. W. Padgett. 1996. *Caenorhabditis elegans* genes *sma-2*, *sma-3*, and *sma-4* define a conserved family of transforming growth factor beta pathway components. *Proc Natl Acad Sci U S A* **93**:790-4.
7. Sekelsky, J. J., S. J. Newfeld, L. A. Raftery, E. H. Chartoff, and W. M. Gelbart. 1995. Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in *Drosophila melanogaster*. *Genetics* **139**:1347-58.
8. Sporn, M. B., and A. B. Roberts. 1985. Autocrine growth factors and cancer. *Nature* **313**:745-7.
9. Sun, L., G. Wu, J. K. Willson, E. Zborowska, J. Yang, I. Rajkarunanayake, J. Wang, L. E.

- Gentry, X. F. Wang, and M. G. Brattain.** 1994. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. *J Biol Chem* **269**:26449-55.
10. **Wrana, J. L., L. Attisano, R. Wieser, F. Ventura, and J. Massague.** 1994. Mechanism of activation of the TGF-beta receptor. *Nature* **370**:341-7.
11. **Yingling, J. M., X. F. Wang, and C. H. Bassing.** 1995. Signaling by the transforming growth factor-beta receptors. *Biochim Biophys Acta* **1242**:115-36.

Mammalian dwarfin proteins are phosphorylated in response to transforming growth factor β and are implicated in control of cell growth

JONATHAN M. YINGLING*, PRADEEP DAS†, CATHY SAVAGE†, MING ZHANG*, RICHARD W. PADGETT†, AND XIAO-FAN WANG*‡

*Department of Pharmacology, Duke University, Durham, NC 27710; and †Waksman Institute, Department of Molecular Biology and Biochemistry and Cancer Institute of New Jersey, P.O. Box 759, Rutgers University, Piscataway, NJ 08855-0759

Communicated by Gordon G. Hammes, Duke University Medical Center, Durham, NC, May 29, 1996 (received for review April 23, 1996)

ABSTRACT The dwarfin protein family has been genetically implicated in transforming growth factor β (TGF- β)-like signaling pathways in *Drosophila* and *Caenorhabditis elegans*. To investigate the role of these proteins in mammalian signaling pathways, we have isolated and studied two murine dwarfin, dwarfin-A and dwarfin-C. Using antibodies against dwarfin-A and dwarfin-C, we show that these two dwarfin and an immunogenically related protein, presumably also a dwarfin, are phosphorylated in a time- and dose-dependent manner in response to TGF- β . Bone morphogenetic protein 2, a TGF- β superfamily ligand, induces phosphorylation of only the related dwarfin protein. Thus, TGF- β superfamily members may use overlapping yet distinct dwarfin to mediate their intracellular signals. Furthermore, transient overexpression of either dwarfin-A or dwarfin-C causes growth arrest, implicating the dwarfin in growth regulation. This work provides strong biochemical and preliminary functional evidence that dwarfin-A and dwarfin-C represent prototypic members of a family of mammalian proteins that may serve as mediators of signaling pathways for TGF- β superfamily members.

Transforming growth factor- β (TGF- β) is a multifunctional polypeptide hormone that elicits a wide range of cellular effects, including inhibition of cellular proliferation and transcriptional activation of specific target genes (1, 2). The TGF- β signal is initiated through a heteromeric transmembrane kinase complex of type I and type II receptors (3–6). A potential mechanism of activation for the heteromeric TGF- β receptor complex has been proposed (7). Within the heteromeric complex, the type II receptor phosphorylates the type I receptor, and activation of the type I receptor initiates the intracellular signaling pathway. However, the cytoplasmic signaling pathway(s) that mediate the TGF- β signal are poorly understood. Although a few proteins that interact with the TGF- β receptors have been identified by the yeast two-hybrid system (8–11) and one potential downstream kinase has been implicated in the TGF- β pathway (12), the precise roles for these proteins in TGF- β signaling remain to be elucidated.

Potential insight into the components of the TGF- β signaling pathways has come from the genetic isolation of a novel family of proteins in *Drosophila* and *Caenorhabditis elegans*. Decapentaplegic (dpp) is the TGF- β -like ligand in *Drosophila* (13). Genetic screens for dominant enhancers of a weak dpp allele led to the isolation of MAD (Mothers against dpp) (14). Loss-of-function mutations in MAD result in similar phenotypic defects as seen with mutant dpp alleles, thus implicating MAD in some aspect of dpp function. *C. elegans* has three MAD homologs, SMA-2, SMA-3, and SMA-4, which have

been implicated in the TGF- β -like pathway in the nematode (15). These four genes define a novel family of proteins called dwarfin (15). Mutant alleles of these genes in *C. elegans* give rise to small worms and fused male tail rays. This phenotype is similar to mutant type II receptor (daf-4) alleles in *C. elegans* (16), thus implicating the sma genes in a pathway downstream of daf-4 (15). Although the genetic evidence strongly suggests that MAD and the SMA proteins participate in TGF- β superfamily signaling pathways in *Drosophila* and *C. elegans*, the biochemical and functional nature of these proteins remains unknown.

These genetic studies prompted us to investigate the potential role of dwarfin in TGF- β signaling pathways in mammalian cells. A human dwarfin homolog, DPC4, has been identified as a candidate tumor suppressor gene in pancreatic carcinomas (17). Therefore, the dwarfin may play an important role in cellular growth control, including the ability to mediate the growth inhibitory signal initiated by TGF- β or TGF- β superfamily members. We report here the isolation and characterization of two murine dwarfin, dwarfin-A (Dwf-A) and dwarfin-C (Dwf-C). Antibodies against these two proteins reveal that three endogenous dwarfin are inducibly phosphorylated in response to TGF- β , but only one of these is phosphorylated in response to bone morphogenetic protein 2 (BMP-2). This is the first indication that the signals for TGF- β superfamily members may be mediated by overlapping, but distinct, intracellular signaling pathways. Inducible phosphorylation of the dwarfin in mammalian systems provides strong support to the genetic evidence that these proteins are mediating some aspect of TGF- β superfamily signaling pathways. Furthermore, transient overexpression of either Dwf-A or Dwf-C causes a growth arrest, which is consistent with their potential role in mediating TGF- β 's growth inhibitory signal.

MATERIALS AND METHODS

Cell Lines. NMuMg (normal murine mammary gland epithelial) and L6 (rat skeletal muscle myoblasts) cells were obtained from the American Type Culture Collection and maintained in DMEM supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin.

Cloning of Dwarfin cDNAs. A 180-nt fragment of Dwf-A was generated by degenerate PCR (15) and used to screen a 12.5-day mouse embryo library to obtain a partial Dwf-A cDNA of 650 bp. The 650-bp EcoRI/XhoI clone was radiolabeled with [32 P]dCTP using the Prime-It II kit from Stratagene

Abbreviations: TGF- β , transforming growth factor β ; BMP-2, bone morphogenetic protein 2; dpp, decapentaplegic; BrdU, bromodeoxyuridine; DH1 and DH2, dwarfin homology domains 1 and 2; Dwf-A, dwarfin-A; Dwf-C, dwarfin-C.

Data deposition: The sequences reported in this paper have been deposited in the GenBank data base [accession nos. U58992 (dwarfin-A) and U58993 (dwarfin-C)].

‡To whom reprint requests should be addressed.

and used to screen a λ gt10 8.5-day mouse embryonic library at low stringency. Briefly, hybridization was at 42°C in 45% formamide, 5× standard saline phosphate/EDTA (SSPE; 0.18 M NaCl/10 mM phosphate, pH 7.4/1 mM EDTA), 5× Denhardt's solution, 0.5% SDS, and 100 μ g/ml salmon sperm DNA for 16–20 hr. The filters were washed two times at room temperature in 2× standard saline citrate (SSC)/0.1% SDS, one time at room temperature in 0.5× SSC/0.1% SDS, and one time in 0.5× SSC/0.1% SDS at 55°C and were exposed overnight. Positive plaques were purified through quaternary screens before the insert was PCR amplified using λ gt10-specific PCR primers (5' primer, AGCAAGTTCAGCTGGTTAAG; 3' primer, 5'-TTATGAGTATTCTTCCAGGG). PCR products were subcloned into pGEM-T (Promega) and partially sequenced with T7 and SP6 primers. This approach isolated a Dwf-A cDNA of 1639 nucleotides and a Dwf-C cDNA of 2185 nucleotides. Both contain an open reading frame of 465 amino acids with a predicted molecular mass of 52 kDa. Subcloning and deletion analysis combined with automated sequencing yielded the nucleotide sequences of Dwf-A and Dwf-C.

Mammalian expression constructs were constructed using *Bam*HI fragments containing full-length cDNAs for Dwf-A and Dwf-C generated by PCR using the following primer sets: Dwf-A 5' primer, 5'-CGCGGATCCGCGATGAATGTGAC-CAGCTTG; Dwf-A 3' primer, 5'-CGCGGATCCGCGCAG-AGTTACCAGGTTTGGC; Dwf-C 5' primer, 5'-CGGGATC-CCGGAATTCATGACGTCAATGGCCAGC; and Dwf-C 3' primer, 5'-CGCGGATCCGCGATGAAGGCAAGAAATT-CC. The resulting PCR products were subcloned into pGEM-T and subsequently into pCMV5 and confirmed by sequencing with a cytomegalovirus promoter-specific sequencing primer: 5'-GCGGTAGGCGTGTACGG-3'.

Northern Analysis. A rat multiple-tissue Northern blot (Clontech) containing 2 μ g of poly(A)⁺ RNA was sequentially probed with the 1.6-kb full-length Dwf-A cDNA followed by the 2.1-kb full-length Dwf-C cDNA. The probes were labeled with [α -³²P]dCTP by random priming (Stratagene) and hybridized for 16–20 hr at 42°C in 50% formamide, 5× SSPE, 5× Denhardt's solution, 0.5% SDS, and 100 μ g/ml salmon sperm DNA. The filters were washed two times at room temperature in 2× SSC/0.1% SDS and two times in 0.2× SSC/0.1% SDS at 60°C. Autoradiography was at –80°C for 18–24 hr with intensifying screens.

Antibody Production. Bacterial expression constructs for Dwf-A and Dwf-C were constructed using the *Bam*HI fragments from pGEM-T Dwf-A or Dwf-C, respectively, to clone in-frame into pGex 2T, generating glutathione *S*-transferase fusion proteins. The resulting \approx 85-kDa fusion proteins were used as antigens for rabbit polyclonal antibody production. Preimmune sera were obtained from each animal before the primary injection of antigen. Both the Dwf-A and Dwf-C antibodies specifically recognize 56-kDa and 52-kDa proteins on Western blots of NMuMg or L6 lysates (data not shown). In addition, transfection of Dwf-A or Dwf-C cDNA into COS cells generates a tight doublet around 52 kDa which cannot account for the two bands seen by Western blotting of endogenous proteins (data not shown). Thus, the 56-kDa protein is most likely immunogenically related to the dwarfins and represents an additional dwarfin family member.

In Vivo Phosphorylation of Endogenous Dwarfins. NMuMg or L6 cells were plated at 1.5×10^6 cells per 100-mm dish and allowed to attach overnight. The cells were rinsed once with phosphate-free media (ICN) and then starved in phosphate-free media containing 0.5% dialyzed FBS (GIBCO/BRL) for 1 hr and then labeled in 0.5% dialyzed FBS with 0.5 mCi/ml (1 Ci = 37 GBq) [³²P]orthophosphate for 4 hr. TGF- β 1 or BMP-2 was added at various concentrations for the indicated length of time at the end of the labeling period. Cells were rinsed twice with ice-cold PBS and lysed in 50 mM Tris (pH


7.5), 100 mM NaCl, 50 mM NaF, 0.5% Nonidet P-40, 1 mM Na₃VO₄, 0.5 mM Na₂MoO₄, 1 mM DTT, 1× protease inhibitors (5 μ g/ml antipain, aprotinin, leupeptin, and trypsin inhibitor; 0.5 μ g/ml pepstatin), and 1 mM phenylmethylsulfonyl fluoride on ice for 15 min. Lysates were microcentrifuged at 14,000 rpm at 4°C for 15 min. The resulting cell lysates were precleared with protein-A Sepharose for 30 min at 4°C. Lysates were then divided for immunoprecipitation with Dwf-A or Dwf-C antibodies. Preimmune or immune sera (20 λ of unpurified sera) was added with Protein-A sepharose for 4 hr at 4°C. The immunoprecipitates were washed three times with lysis buffer before separation in SDS/8% polyacrylamide followed by autoradiography at room temperature.

Transient Growth Arrest Assay. The following procedure was adapted from DeGregori and coworkers (18). L6 cells were plated in six-well trays on poly-L-lysine-coated coverslips at 10^5 cells per well and allowed to attach overnight. CellFectin (GIBCO/BRL) was used to transfect the cells with 2 μ g of pCMV LacZ and 8 μ g of vector alone, Dwf-A, or Dwf-C for 10 hr in DMEM. The cells were incubated in 10% FBS for 36 hr before immunohistochemical staining. Media containing 20 μ M bromodeoxyuridine (BrdU) was added for the last 20 hr to metabolically label dividing cells. The cells were fixed in 4% paraformaldehyde in PBS, permeabilized with MeOH/acetone, and stained with a 1:500 dilution of rabbit anti- β -galactosidase antibody (5 Prime–3 Prime, Inc.) in 1% BSA/PBS for 60 min, followed by a fluorescein isothiocyanate-conjugated goat anti-rabbit secondary antibody (Boehringer Mannheim) at 1:500 in 1% BSA/PBS to stain transfected cells. After a second fixation and 2 M HCl permeabilization for 45 min, the cells were stained with a mouse anti-BrdU antibody (Zymed) at 1:3 in 1% BSA/PBS followed by a goat anti-mouse rhodamine-conjugated secondary antibody (Pierce) at 1:100 in 1% BSA/PBS. Finally, 4 μ g/ml Hoeschst 33342 in PBS was used to counter-stain the DNA. The coverslips were mounted in 1,4-diazabicyclo[2.2.2]octane and analyzed by fluorescence microscopy.

RESULTS

Cloning of Dwf-A and Dwf-C. Full-length cDNAs for Dwf-A and Dwf-C were isolated by low stringency hybridization of a 8.5-day mouse embryonic library as described in *Materials and Methods*. The amino acid sequences of Dwf-A and Dwf-C are 95% homologous and 90% identical. Both contain the characteristic dwarfin homology domain 1 (DH1) and dwarfin homology domain 2 (DH2) motifs separated by a proline-rich linker region (Fig. 1A; ref. 15). Dwf-A and Dwf-C are about 80% homologous to the *Drosophila* dwarfin, MAD (Fig. 1A; ref. 14), and the *C. elegans* dwarfin, SMA-2 (Fig. 1A; ref. 15). Dwf-A and Dwf-C are distantly related to the only other known mammalian dwarfin, DPC4 (60% homologous, 40% identity; ref. 17), and thus likely represent a distinct family of mammalian dwarfins (Fig. 1B). Northern analysis showed that both genes are ubiquitously expressed (Fig. 1C). The mRNA message of Dwf-A is \approx 3.5 kb, whereas Dwf-C has two messages of \approx 8 and \approx 3 kb.

TGF- β Induces Phosphorylation of Endogenous Dwarfins. We chose two cell lines, NMuMg (19) and L6, which are potently growth inhibited by TGF- β , as model systems to study endogenous dwarfin phosphorylation. Antibodies against Dwf-A or Dwf-C were used to determine if the levels or phosphorylation state of endogenous dwarfins were modulated by TGF- β . The expression levels of dwarfins were unchanged at any time within 24 hr after TGF- β treatment as determined by Western blot analysis (data not shown). However, TGF- β induced rapid, but transient, phosphorylation of Dwf-A, Dwf-C, and a 56-kDa immunogenically related protein (Fig. 2A).




lated to a similar extent and with similar kinetics in both cell lines. Dwf-C was phosphorylated with the same kinetics as in NMuMg cells, but with a reduced extent due to increased basal phosphorylation in the absence of TGF- β in L6 cells (Fig. 2C).

To ensure that TGF- β was capable of inducing phosphorylation of the dwarfins at more physiological concentrations, we determined the dose dependence of dwarfin phosphorylation in NMuMg cells. Dwf-A, Dwf-C, and the 56-kDa protein were all inducibly phosphorylated by 10 pM TGF- β (Fig. 3), a concentration capable of eliciting the various biological effects of TGF- β .

BMP-2 Induces Phosphorylation of Endogenous Dwarfins. TGF- β -like ligands from *Drosophila* and *C. elegans* are most closely related to mammalian BMPs (16, 20). BMPs have been shown to elicit multiple effects, including inhibition of cellular proliferation, on many different cell types (21). Like TGF- β , BMP-2 has been shown to initiate its signaling cascade by

Immunoprecipitation of Dwf-A and Dwf-C from L6 cells gave nearly identical results as those from NMuMg cells (Fig. 2 *C* and *D*). Dwf-A and the 56-kDa protein were phosphory-






FIG. 3. TGF- β phosphorylation of endogenous dwarfin is dose-dependent. Dwf-A and Dwf-C immunoprecipitation from NMuMg cells was performed as in Fig. 2 except various doses of TGF- β 1 were added for 1 hr.

binding to a heteromeric complex of transmembrane serine-threonine kinase receptors at the cell surface (22). However, the similarity between the cytoplasmic pathways that lead to the biological effects of TGF- β and BMP-2 is unknown. The NMuMg cell line is potentially inhibited by BMP-2, affording us the opportunity to determine if dwarfin phosphorylation is induced by BMP-2. As shown in Fig. 4 *A* and *B*, phosphorylation of the 56-kDa protein is induced by BMP-2 within 15 min and peaks at 2.5-fold in 60 min. Interestingly, Dwf-A and Dwf-C, which are inducibly phosphorylated in response to TGF- β , are not phosphorylated in BMP-2-treated NMuMg cells (Fig. 4*A*).

Dwf-A and Dwf-C Are Implicated in Cell Growth Regulation. Attempts to establish stable cell lines constitutively overexpressing either Dwf-A in L6 cells or Dwf-C in NMuMg cells were unsuccessful. This result was not unexpected because the dwarfin are suspected to have growth-suppressive effects based on the tumor suppressor activity of DPC4 (17). Consequently, we used a modified transient growth assay (18) to assess the ability of Dwf-A or Dwf-C to cause a growth arrest when transiently transfected into L6 cells. Constitutive overexpression of Dwf-A or Dwf-C caused 30–40% growth inhibition compared with 10% for control vector transfectants (Fig. 5). Therefore, Dwf-A and Dwf-C, like DPC4, exhibit growth-inhibitory properties, implicating these dwarfin proteins in cell growth regulation.

DISCUSSION

Identification of downstream effectors for TGF- β or TGF- β superfamily members has proven elusive. Mutagenesis studies in mammalian cells have yielded only receptor mutants (23, 24), which suggests the existence of redundant pathways downstream of the receptors. Fortunately, TGF- β -like path-

ways exist in genetically tractable organisms to allow the use of genetics to identify components of these signaling pathways. Many of these components (e.g., receptors, accessory molecules, and ligands) have been shown to have homologous counterparts in vertebrate systems. Consequently, we have studied two mammalian homologs of MAD and SMA-2 as potential downstream effectors of the TGF- β signaling pathway. We provide biochemical evidence that the dwarfin family of proteins is involved in TGF- β and BMP-2 signaling pathways in mammalian systems. Furthermore, results from a modified transient growth assay and preliminary studies with potentially dominant negative forms of Dwf-A (unpublished data) strongly implicate a role for the dwarfin as mediators of the TGF- β growth-regulatory signal.

Although the dwarfin do not contain any known catalytic motifs, their DH1 and DH2 domains are reminiscent of Src homology 2 and 3 domains, which in a variety of signaling pathways modulate protein–protein interactions based on tyrosine phosphorylation and proline-rich sequences, respectively (25). TGF- β and BMP-2-induced phosphorylation of the dwarfin may regulate protein–protein interactions in an analogous fashion for TGF- β superfamily signaling cascades. Recently, 14-3-3 proteins have been shown to be specific phosphoserine-binding proteins that are critical for the activation of signaling proteins (26). This suggests a novel role for serine–threonine phosphorylation in the assembly of protein–protein complexes required to transduce certain intracellular signals. Serine–threonine phosphorylation of the dwarfin may regulate their ability to serve as adaptor molecules for other effectors in the TGF- β pathway or regulate their ability to specifically bind other intracellular proteins. These protein–protein interactions may result in altered subcellular distribution of the dwarfin. Preliminary immunofluorescence studies in NMuMg cells indicate that the dwarfin are predominantly




FIG. 4. BMP-2-induced phosphorylation of endogenous dwarfin. (*A*) Immunoprecipitation with Dwf-A (*Left*) or Dwf-C (*Right*) antibodies was performed on NMuMg cells treated for the indicated length of time with 100 ng/ml BMP-2. (*B*) Quantitation of BMP-2-induced dwarfin phosphorylation in NMuMg cells. The 52-kDa Dwf-A band (●) and the 56-kDa protein in α Dwf-A (○) or α Dwf-C (□) immunoprecipitates were quantitated. The 52-kDa Dwf-C band that is not basally phosphorylated in NMuMg cells is undetectable after BMP-2 treatment. The level of phosphorylation was standardized using the 68-kDa background band and two additional background bands.




FIG. 5. Dwf-A and Dwf-C cause a growth arrest in L6 cells. L6 cells were transfected and immunohistochemically stained as described in *Materials and Methods*. All the transfected cells (fluorescein isothiocyanate stained) on each coverslip were scored for BrdU incorporation (rhodamine stained). All (100%) of the nontransfected cells incorporate BrdU during the labeling period; therefore, the percentage of transfected cells that are BrdU-negative represents the percent growth inhibition caused by transfection of the cDNA. Data shown are the mean \pm SD of at least three experiments.

localized in the cytoplasm (unpublished data). Although TGF- β or BMP-2 treatment does not appear to cause a significant change in the subcellular distribution of the dwarfins, it is possible that a minor proportion of dwarfins that become phosphorylated accumulate at the membrane or translocate to the nucleus to fulfill their biological function. Indeed, a human homolog of Dwf-A, MADR1, has recently been shown to be inducibly phosphorylated and to translocate to the nucleus after BMP-2 treatment (27). Intriguingly, phosphorylation of MADR1 appears to be BMP-2-specific in their system, since neither TGF- β nor activin induces MADR1 phosphorylation. This apparent discrepancy may be due to differences in experimental systems, overexpression of epitope-tagged MADR1 instead of endogenous dwarfins, or may represent cell-type specific differences in the pathways used by TGF- β superfamily ligands. Clarification of this issue requires further study.

Our initial attempt to study TGF- β 's ability to modulate the phosphorylation state of Dwf-A and Dwf-C involved transfection of hemagglutinin epitope-tagged cDNAs into COS or mink lung epithelial cells. Although both proteins are phosphorylated in these systems, the high level of constitutive phosphorylation precluded detection of TGF- β induced changes in Dwf-A or Dwf-C phosphorylation (unpublished data). Interestingly, the *C. elegans* dwarfins, SMA-2 and SMA-3, are not phosphorylated when overexpressed in COS cells. Therefore, the observed phosphorylation is likely a result of phosphorylation by an associated kinase that is unable to recognize SMA-2 or SMA-3 as substrates. The unique serine-threonine-rich insert in the linker region of Dwf-A and Dwf-C (Fig. 1A) may play a role in either kinase recognition or as targets of phosphorylation by the associated kinase. Preliminary results indicate that neither Dwf-A nor Dwf-C are substrates of the type I or type II TGF- β receptor kinases (unpublished data), implicating an as yet unidentified kinase in phosphorylation of the dwarfins.

The differential phosphorylation of endogenous dwarfins in response to TGF- β and BMP-2 suggests that the specific dwarfins used by TGF- β superfamily members may vary. In support of this notion, two related *Xenopus* dwarfins (Xmad1 and Xmad2) have been shown to mediate either BMP-2/BMP-4 signals or Vg1/activin/nodal signals, respectively (28). Thus, Dwf-A and Dwf-C may represent TGF- β -specific dwarfins, whereas the 56-kDa dwarf in is shared by TGF- β and BMP-2. The differential response of these proteins to TGF- β and BMP-2 will facilitate elucidation of the differences in the intracellular pathways used by these two members of the TGF- β superfamily.

We wish to thank S.-J. Lee for the 12.5-day mouse embryonic library and B. Hogan for the 8.5-day mouse embryonic library; Genetics Institute for recombinant human BMP-2; Amgen for recombinant human TGF- β 1; Y. Xiong for automated sequencing assistance; J. Heitman and M. Caron for critical review of the manuscript; C. Bassing, D. Cortez, M. Datto, P. Hu, G. Reuther, and H. Symonds for helpful discussion; and Y. Yu and H. Wang for technical help. J.M.Y. thanks M. L. Yingling for her constant support and encouragement. This work was supported by U.S. Army Breast Cancer Research Program Grant DAMD17-945-4065 (X.-F.W.), National Institutes of Health Grant GM47395 (R.W.P.); and Council for Tobacco Research Grant 3639 (R.W.P.). J.M.Y. was supported by a U.S. Army Breast Cancer Research Program Predoctoral Fellowship (DAMD17-94-J-4190). P.D. is a Busch Predoctoral Fellow, and C.S. is a New Jersey Cancer Commission Postdoctoral Fellow; X.-F.W. is a Leukemia Society Scholar.

- Massague, J. (1990) *Annu. Rev. Cell Biol.* **6**, 597-641.
- Roberts, A. B. & Sporn, M. B. (1990) in *Handbook of Experimental Pharmacology, Peptide Growth Factors and their Receptors*, eds. Sporn, M. B. & Roberts, A. B. (Springer, Heidelberg), pp. 419-472.
- Lin, H. Y., Wang, X.-F., Ng-Eaton, E., Weinberg, R. A. & Lodish, H. F. (1992) *Cell* **68**, 775-785.
- Wrana, J. L., Attisano, L., Carcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X.-F. & Massague, J. (1992) *Cell* **71**, 1003-1014.
- Franzen, P., ten Dijke, P., Ichijo, H., Yamashita, H., Schulz, P., Heldin, C.-H. & Miyazono, K. (1993) *Cell* **75**, 681-692.
- Bassing, C. H., Yingling, J. M., Howe, D. J., Wang, T., He, W. W., Gustafson, M. L., Shah, P., Donahoe, P. K. & Wang, X.-F. (1994) *Science* **263**, 87-89.
- Wrana, J. L., Attisano, L., Weiser, R., Ventura, F. & Massague, J. (1994) *Nature (London)* **370**, 341-347.
- Wang, T. W., Donahoe, P. K. & Zervos, A. S. (1994) *Science* **265**, 674-676.
- Chen, R. H., Miettinen, P. J., Maruoka, E. M., Choy, L. & Derynck, R. (1995) *Nature (London)* **377**, 548-552.
- Kawabata, M., Imamura, T., Miyazono, K., Engel, M. E. & Moses, H. L. (1995) *J. Biol. Chem.* **270**, 29628-29631.
- Wang, T. W., Danielson, P. D., Li, B.-y., Shah, P. C., Kim, S. D. & Donahoe, P. K. (1996) *Science* **271**, 1120-1122.
- Yamaguchi, K., Shirakabe, K., Shibuya, H., Irie, K., Oishi, I., Ueno, N., Taniguchi, T., Nishida, E. & Matsumoto, K. (1996) *Science* **270**, 2008-2011.
- Padgett, R. W., St. Johnston, R. D. & Gelbart, W. M. (1987) *Nature (London)* **325**, 81-84.
- Sekelsky, J. J., Newfeld, S. J., Raftery, L. A., Chartoff, E. H. & Gelbart, W. M. (1995) *Genetics* **139**, 1347-1358.
- Savage, C., Das, P., Finelli, A. L., Townsend, S. R., Sun, C.-Y., Baird, S. E. & Padgett, R. W. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 790-794.
- Estevez, M., Attisano, L., Wrana, J. L., Albert, P. S., Massague, J. & Riddle, D. L. (1993) *Nature (London)* **364**, 644-649.
- Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H. & Kern, S. E. (1996) *Science* **271**, 350-353.
- DeGregori, J., Kowalik, T. & Nevins, J. R. (1995) *Mol. Cell Biol.* **15**, 4215-4224.
- Miettinen, P. J., Ebner, R., Lopez, A. R. & Derynck, R. (1994) *J. Cell Biol.* **127**, 2021-2036.
- Maliakal, J. C., Asahina, I., Hauschka, P. V. & Sampath, T. K. (1994) *Growth Factors* **11**, 227-234.
- Yamashita, H., ten Dijke, P., Huylebroeck, D., Sampath, T. K., Andries, M., Smith, J. C., Heldin, C.-H. & Miyazono, K. (1995) *J. Cell Biol.* **130**, 217-226.
- Liu, F., Ventura, F., Doody, J. & Massague, J. (1995) *Mol. Cell Biol.* **15**, 3479-3486.
- Boyd, F. & Massague, J. (1989) *J. Biol. Chem.* **264**, 2272-2278.
- Laiho, M., Weis, F. M. B. & Massague, J. (1990) *J. Biol. Chem.* **265**, 18518-18524.
- Cohen, G. B., Ren, R. & Baltimore, D. (1995) *Cell* **80**, 237-248.
- Muslin, A. J., Tanner, J. W., Allen, P. M. & Shaw, A. S. (1996) *Cell* **84**, 889-897.
- Hoodless, P. A., Haerry, T., Abdollah, S., Stapleton, M., O'Connor, M. B., Attisano, L. & Wrana, J. L. (1996) *Cell* **85**, 489-500.
- Graff, J. M., Bansal, A. & Melton, D. A. (1996) *Cell* **85**, 479-487.